



NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

AMORFIX CLOSES \$3.3 MILLION PRIVATE PLACEMENT

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES
NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Ontario – April 29, 2009 – Amorfix Life Sciences Ltd. announced today that it has closed a non-brokered private placement, pursuant to which a total of 5,146,300 units (Units) were issued at a price of \$0.65 per Unit for gross proceeds of \$3,345,095. The size of the offering was increased from the amount previously announced to accommodate over-subscriptions.

Amorfix intends to use the net proceeds of the private placement to advance the development and commercialization of its diagnostic tests including its EP-vCJD™ blood screening assay and for general corporate purposes.

Each issued Unit consisted of one common share and one-half of one common share purchase warrant (Warrant). Each whole Warrant is exercisable into one common share of Amorfix at a price of \$1.00 for a period of 24 months, subject to earlier expiry in the event (a trigger event) that, following the expiry of the four month hold period, the volume-weighted average price of Amorfix's common shares on the TSX over a period of ten consecutive trading days exceeds \$1.20. On the occurrence of a trigger event, Amorfix may give notice to holders to accelerate the expiry to a date which is not less than 30 calendar days after such notice is sent to the holders.

In connection with the private placement, Amorfix paid \$226,460 in finder fees and issued 348,400 finder warrants. Each finder warrant is exercisable into one common share of Amorfix at a price of \$0.68 for a period of 24 months, subject to earlier expiry on the occurrence of a trigger event on the same terms as applies to the Warrants.

All of the securities issued in connection with the private placement are subject to four month hold periods that expire on August 29, 2009.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Amorfix

Amorfix Life Sciences Ltd. (TSX: AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded diseases including neurodegenerative diseases and cancer. It has specific programs in vCJD, ALS and Alzheimer's disease. Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample containing normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and cancer. Amorfix has shown antibodies and vaccines to misfolded proteins are therapeutic in preclinical animal models. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

For more information, please contact:

Dr. George Adams
President & Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6959
Fax: (416) 847-6899
george.adams@amorfix.com

James Parsons
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6929
Fax: (416) 847-6899
james.parsons@amorfix.com